Newswise — (PHILADELPHIA) A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University’s Kimmel Cancer Center.
The finding, published online this month in the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy for advanced inflammatory breast cancer (IBC).
“Because this kind of breast cancer is very difficult to treat, we hope this new combination of anticancer agents will change the outcome of this aggressive disease,” says the study’s senior investigator, Massimo Cristofanilli, M.D., F.A.C.P., Professor of Medical Oncology and Director of the Jefferson Breast Care Center.
The study was conducted in collaboration with the lead author, Fredika Robertson, Ph.D., at The University of Texas M. D. Anderson Cancer Center, and was supported by a Promise Grant from the Susan G Komen Foundation awarded to Drs. Cristofanilli and Robertson in 2008.
Inflammatory breast cancer (IBC) is the most metastatic variant of locally advanced breast cancer, Dr. Cristofanilli says. Although it accounts for between 2-5 percent of all breast cancers in the United States — and 13 percent of breast cancers globally — it is responsible for a disproportionate number of deaths from breast cancer, he says.
One of the reasons for the lethality of inflammatory breast cancer is that early in the disease onset it produces emboli — small balls of cancer cells — which spread through the lymph system causing the typical breast swelling. These aggregates of cancer cells are resistant to chemotherapy, radiation, and are believed to be responsible for rapid metastasis, Dr. Cristofanilli says.
Experiments in laboratory cells and in mice models of inflammatory breast cancer demonstrates that Romidepsin is able to break the bonds that bind the cancer cells together, which then allows chemotherapy to effectively target single cancer cells, he says.
Romidepsin is a histone deacetylase (HDAC) inhibitor, a new class of drugs that regulates gene transcription in a unique way.
This study tested two other HDAC inhibitors, but found Romidepsin offered the best results. The agent was approved for use to treat cutaneous T-cell lymphoma in 2009. It is also undergoing clinical trials for use in other lymphomas.
“This study is a nice example of a transition from the laboratory to the clinic,” says Dr. Cristofanilli. “Our laboratory work suggested it might be helpful to treat inflammatory breast cancer, and now we are about to open a clinical trial to test that very promising possibility.”
The study was supported by the American Airlines-Komen For the Cure Organization Promise Grant KG081287 (FMR, MC) and Celgene Corporation. The authors declare that they have no conflicts of interest.
Thomas Jefferson University (TJU), the largest freestanding academic medical center in Philadelphia, is nationally renowned for medical and health sciences education and innovative research. Founded in 1824, TJU includes Jefferson Medical College (JMC), one of the largest private medical schools in the country and ranked among the nation’s best medical schools by U.S. News & World Report, and the Jefferson Schools of Nursing, Pharmacy, Health Professions, Population Health and the Graduate School of Biomedical Sciences. Jefferson University Physicians is TJU’s multi-specialty physician practice consisting of the full-time faculty of JMC. Thomas Jefferson University partners with its clinical affiliate, Thomas Jefferson University Hospitals.
Article Reference: F.M. Robertson et al., “The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis,” JETO, 10:219-233, 2013.